^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) + Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.
Published date:
05/19/2021
Excerpt:
Whole exome sequencing was performed on available tumor tissues and PD-L1 expression was determined by immunohistochemistry staining….High ORR was significantly associated with positive PD-L1 expression (p= 0.048)….Gemox chemotherapy in combination with Anti-PD1 antibody Toripalimab and Lenvatinib provided remarkable efficacy with reasonable tolerability in advanced ICC patients.
Secondary therapy:
GemOx
DOI:
10.1200/JCO.2021.39.15_suppl.4094
Trial ID:
Source:
Title:
56P - Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
Published date:
09/14/2020
Excerpt:
The combination of toripalimab, lenvatinib with Gemox chemotherapy was tolerable and showed promising ORR in patients with advanced ICC. ORR was significantly associated with PD-L1 expression and DNA damage repair (DDR)-related mutations in tumor samples.
Secondary therapy:
GemOx
Trial ID:
